In a related editorial, the author discusses the potential mode of action when using both drugs, suggesting that adding semaglutide to SGLT-2 inhibitors seems to be a rational approach to combination therapy, although more information will be required to appreciate the full potential of this treatment in the clinical setting. The author also notes the study is too short to assess the durability of the glucose-lowering efficacy, but both drugs have been shown to exert persistent glycaemic control. “Compared with sulfonylureas, SGLT-2 inhibitors have better durability and lower rates of worsening of HbA1c over time”.